Skip to main content

The mechanism of action of risperidone in schizophrenia is unclear. The drug’s therapeutic activity could be mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.1

Image of risperidone diffusing from the solid depot within the subcutaneous tissue.

Sustained release following depot formation

Risperidone is released on initial depot formation, followed by sustained drug release from the depot over the entire monthly dosing period1

Risperidone and paliperidone

Combined metabolic action

The clinical effect of PERSERIS results from the combined concentrations of risperidone and its major metabolite, paliperidone (i.e., total active moiety)1

PERSERIS is presumed to bind to the following receptors1

Image of PERSERIS binding to receptors.

Therapeutic activity

The antipsychotic effects of PERSERIS are thought to occur through D2 and 5HT2 receptor antagonism. Antagonism at receptors other than D2 and 5HT2 may explain some of the other effects of risperidone1